IHS4 kalkulátor — hidradenitis suppurativa
Hidradenitis suppurativa (HS) klinikai súlyosságának számszerűsítése; IHS4 pontszám számítása.
További információk
Figyelmeztetés
Ez az eszköz kizárólag oktatási célra szolgál, és nem jelent vagy helyettesít szakmai tanácsot. Az eszköz nem használható orvosi diagnózis felállítására és/vagy orvosi kezelés nyújtására.
General description
Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory disease presenting as painful subcutaneous nodules that most commonly affects areas with apocrine sweat glands, such as the axillae, groin, and the gluteal area. The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool for dynamically assessing the severity of HS.
The IHS4 score is calculated by adding the number of nodules, abscesses, and draining tunnels, with different weights for each type of lesion. A total score of 3 or less signifies mild, 4–10 signifies moderate, and 11 or higher signifies severe disease. IHS4 emphasizes the role of draining tunnels, which are a major feature of HS.
The IHS4 score can be used to monitor disease progression and treatment response in patients with HS. It has been validated as a tool to assess HS severity in both real-life and clinical trial settings.
Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory disease presenting as painful subcutaneous nodules that most commonly affects areas with apocrine sweat glands, such as the axillae, groin, and the gluteal area. The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool for dynamically assessing the severity of HS.
The IHS4 score is calculated by adding the number of nodules, abscesses, and draining tunnels, with different weights for each type of lesion. A total score of 3 or less signifies mild, 4–10 signifies moderate, and 11 or higher signifies severe disease. IHS4 emphasizes the role of draining tunnels, which are a major feature of HS.
The IHS4 score can be used to monitor disease progression and treatment response in patients with HS. It has been validated as a tool to assess HS severity in both real-life and clinical trial settings.
Mild hidradenitis suppurativa
≤ 3 pointsModerate hidradenitis suppurativa
4–10 pointsSevere hidradenitis suppurativa
≥ 11 pointsFormula
IHS4 (points) = number of nodules x 1 + number of abscesses x 2 + number of draining tunnels (fistulae/sinuses) x 4
References
Zouboulis CC, et al.; European Hidradenitis Suppurativa Foundation Investigator Group. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol. 2017 Nov;177(5):1401-1409
Verzió
1
Az eszközről
Hidradenitis Suppurativa (HS) is a chronic, recurrent, inflammatory disease presenting as painful subcutaneous nodules that most commonly affects areas with apocrine sweat glands, such as the axillae, groin, and the gluteal area. The International Hidradenitis Suppurativa Severity Score System (IHS4) is a validated tool for dynamically assessing the severity of HS.
The IHS4 score is calculated by adding the number of nodules, abscesses, and draining tunnels, with different weights for each type of lesion. A total score of 3 or less signifies mild, 4–10 signifies moderate, and 11 or higher signifies severe disease. IHS4 emphasizes the role of draining tunnels, which are a major feature of HS.
The IHS4 score can be used to monitor disease progression and treatment response in patients with HS. It has been validated as a tool to assess HS severity in both real-life and clinical trial settings.
The IHS4 score is calculated by adding the number of nodules, abscesses, and draining tunnels, with different weights for each type of lesion. A total score of 3 or less signifies mild, 4–10 signifies moderate, and 11 or higher signifies severe disease. IHS4 emphasizes the role of draining tunnels, which are a major feature of HS.
The IHS4 score can be used to monitor disease progression and treatment response in patients with HS. It has been validated as a tool to assess HS severity in both real-life and clinical trial settings.
